Kestra Medical Technologies (NASDAQ:KMTS) Director Conor Hanley Sells 5,694 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Conor Hanley sold 5,694 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total transaction of $143,773.50. Following the sale, the director directly owned 6,272 shares of the company’s stock, valued at $158,368. The trade was a 47.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

KMTS opened at $23.57 on Friday. The company’s 50 day moving average is $25.42 and its 200 day moving average is $22.71. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -9.74 and a beta of 0.62. Kestra Medical Technologies, Ltd. has a 12-month low of $17.34 and a 12-month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million for the quarter. On average, equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to the executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development efforts. He will oversee innovation for the Cardiac Recovery System platform, including strategic partnerships and artificial-intelligence initiatives. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, indicating no measurable short-selling pressure based on the filing data. However, the figure provides little incremental insight because it was also reported as zero in the prior period.
• Negative Sentiment: Four directors disclosed sales totaling about 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by roughly 9% to 48%. All four sales were explicitly made to cover tax-withholding obligations tied to vested equity awards, which makes them less bearish than discretionary open-market selling, but the cluster of transactions may still pressure sentiment. SEC insider transaction filing
• Negative Sentiment: Kestra’s latest reported quarter included an adjusted loss of $0.67 per share, worse than the $0.59 analyst consensus, alongside $28.64 million in revenue. The company remains unprofitable, increasing investor sensitivity to execution, product adoption and commercialization risks.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter worth about $72,000. Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares during the period. Finally, New York State Common Retirement Fund bought a new position in Kestra Medical Technologies in the 2nd quarter worth approximately $93,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on KMTS shares. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Oppenheimer began coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.14.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.